Product Information
NEOMYCIN-POLYMYXIN-HC EAR SOLN is a generic product labeled by Bausch & Lomb Incorporated, priced at $5.0895 per ML under NDC 24208063110. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 29, 1995. Its Orange Book therapeutic-equivalence code is AT.
Strength
10; 3.5; 10000 mg/mL; mg/mL; [USP'U]/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208063110
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
AURICULAR (OTIC)
Effective Date
9/23/2026
Active Ingredients
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064053FDA Approved
12/29/1995
TE Code
AT
On Market Since
12/29/1995
Pharmacological Classes
Price Statistics
The NADAC for NEOMYCIN-POLYMYXIN-HC EAR SOLN has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 170.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.0895 per ML |
|---|---|
| All-time high | $6.5838 (Oct 13, 2021) |
| All-time low | $1.7627 (Sep 23, 2015) |
| 52-week high | $5.3795 |
| 52-week low | $5.0754 |
| Median price | $5.3275 |
| Average price | $4.8870 |
| Largest weekly change | +200.5% (Oct 21, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Neomycin Sulfate, Polymyxin B Sulfate, Hydrocortisone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Neomycin Sulfate, Polymyxin B Sulfate, Hydrocortisone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEOMYCIN-POLYMYXIN-HC EAR SOLN?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYCIN-POLYMYXIN-HC EAR SOLN, manufactured by Bausch & Lomb Incorporated, is $5.0895 per ML (NDC 24208063110), effective Sep 30, 2026.
How has the price of NEOMYCIN-POLYMYXIN-HC EAR SOLN changed over time?
Over the history we have for it, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SOLN has risen 170.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEOMYCIN-POLYMYXIN-HC EAR SOLN?
Since Nov 28, 2013, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SOLN has ranged from a low of $1.7627 (Sep 23, 2015) to a high of $6.5838 (Oct 13, 2021), with a median of $5.3275 per ML.
Are there cheaper alternatives to NEOMYCIN-POLYMYXIN-HC EAR SOLN?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYCIN-POLYMYXIN-HC EAR SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYCIN-POLYMYXIN-HC EAR SOLN?
NEOMYCIN-POLYMYXIN-HC EAR SOLN (NDC 24208063110) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.